Johnson & Johnson buys 18 percent stake in Crucell

AMSTERDAM (Reuters) – U.S. diversified health care company Johnson & Johnson has bought an 18 percent stake in biotech firm Crucell for 302 million euros ($444 million) as part of a flu vaccine development deal, the Dutch company said on Monday.

Leave a Reply